Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176


p53 oligomerization and DNA looping are linked with transcriptional activation.

Stenger JE, Tegtmeyer P, Mayr GA, Reed M, Wang Y, Wang P, Hough PV, Mastrangelo IA.

EMBO J. 1994 Dec 15;13(24):6011-20.


Interaction of p53 with its consensus DNA-binding site.

Wang Y, Schwedes JF, Parks D, Mann K, Tegtmeyer P.

Mol Cell Biol. 1995 Apr;15(4):2157-65.


Synergistic transcriptional activation of the MCK promoter by p53: tetramers link separated DNA response elements by DNA looping.

Jackson P, Mastrangelo I, Reed M, Tegtmeyer P, Yardley G, Barrett J.

Oncogene. 1998 Jan 15;16(2):283-92.


p53 domains: identification and characterization of two autonomous DNA-binding regions.

Wang Y, Reed M, Wang P, Stenger JE, Mayr G, Anderson ME, Schwedes JF, Tegtmeyer P.

Genes Dev. 1993 Dec;7(12B):2575-86.


Interaction of human polyomavirus BK with the tumor-suppressor protein p53.

Shivakumar CV, Das GC.

Oncogene. 1996 Jul 18;13(2):323-32.


Insights into selective activation of p53 DNA binding by c-Abl.

Wei G, Li AG, Liu X.

J Biol Chem. 2005 Apr 1;280(13):12271-8. Epub 2005 Jan 20.


DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53.

Kim E, Albrechtsen N, Deppert W.

Oncogene. 1997 Aug 14;15(7):857-69. Erratum in: Oncogene 1997 Nov 6;15(19):2385.


Tumor suppressor protein p53 binds preferentially to supercoiled DNA.

Palecek E, Vlk D, Stanková V, Brázda V, Vojtesek B, Hupp TR, Schaper A, Jovin TM.

Oncogene. 1997 Oct;15(18):2201-9.


Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.

Kong XT, Gao H, Stanbridge EJ.

J Biol Chem. 2001 Aug 31;276(35):32990-3000. Epub 2001 Jun 6.


Discrimination of DNA binding sites by mutant p53 proteins.

Thukral SK, Lu Y, Blain GC, Harvey TS, Jacobsen VL.

Mol Cell Biol. 1995 Sep;15(9):5196-202.


Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA.

Balagurumoorthy P, Sakamoto H, Lewis MS, Zambrano N, Clore GM, Gronenborn AM, Appella E, Harrington RE.

Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8591-5.


Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.

Jordan JJ, Menendez D, Inga A, Noureddine M, Bell DA, Resnick MA.

PLoS Genet. 2008 Jun 27;4(6):e1000104. doi: 10.1371/journal.pgen.1000104. Erratum in: PLoS Genet. 2008 Nov;4(11) PLoS Genet. 2008 Jul;4(7). doi: 10.1371/annotation/13bc83be-2345-401d-b953-f1886e9fbdff. Nourredine, Maher [corrected to Noureddine, Maher]; Bell, Douglas [corrected to Bell, Douglas A].


High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops.

Stros M, Muselíková-Polanská E, Pospísilová S, Strauss F.

Biochemistry. 2004 Jun 8;43(22):7215-25.


Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain.

Göhler T, Reimann M, Cherny D, Walter K, Warnecke G, Kim E, Deppert W.

J Biol Chem. 2002 Oct 25;277(43):41192-203. Epub 2002 Aug 8.


Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.

Kaku S, Iwahashi Y, Kuraishi A, Albor A, Yamagishi T, Nakaike S, Kulesz-Martin M.

Nucleic Acids Res. 2001 May 1;29(9):1989-93.


The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region.

Selivanova G, Iotsova V, Kiseleva E, Ström M, Bakalkin G, Grafström RC, Wiman KG.

Nucleic Acids Res. 1996 Sep 15;24(18):3560-7.


DNA bending due to specific p53 and p53 core domain-DNA interactions visualized by electron microscopy.

Cherny DI, Striker G, Subramaniam V, Jett SD, Palecek E, Jovin TM.

J Mol Biol. 1999 Dec 10;294(4):1015-26.


Two functionally divergent p53-responsive elements in the rat bradykinin B2 receptor promoter.

Marks J, Saifudeen Z, Dipp S, El-Dahr SS.

J Biol Chem. 2003 Sep 5;278(36):34158-66. Epub 2003 Jun 5.


Identification of a DNA element that can enhance p53-mediated transactivation.

Shiio Y, Yamamoto T, Yamaguchi N.

Oncogene. 1993 Aug;8(8):2059-65.

Items per page

Supplemental Content

Write to the Help Desk